9 analysts have expressed a variety of opinions on Merck & Co MRK over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 7 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 3 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 1 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $130.56, along with a high estimate of $135.00 and a low estimate of $115.00. Observing a 8.8% increase, the current average has risen from the previous average price target of $120.00.
Breaking Down Analyst Ratings: A Detailed Examination
The perception of Merck & Co by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $135.00 | - |
| Steve Scala | TD Cowen | Raises | Outperform | $135.00 | $125.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $135.00 | - |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $135.00 | - |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $135.00 | - |
| James Shin | Deutsche Bank | Announces | Buy | $115.00 | - |
| Terence Flynn | Morgan Stanley | Raises | Equal-Weight | $118.00 | $115.00 |
| Evan David Seigerman | BMO Capital | Announces | Outperform | $132.00 | - |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $135.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Merck & Co. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Merck & Co compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Merck & Co's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Merck & Co's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Merck & Co analyst ratings.
Delving into Merck & Co's Background
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Merck & Co's Financial Performance
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Merck & Co's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.71% as of 30 September, 2023, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Merck & Co's net margin excels beyond industry benchmarks, reaching 29.73%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Merck & Co's ROE stands out, surpassing industry averages. With an impressive ROE of 11.87%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Merck & Co's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.49%, the company showcases efficient use of assets and strong financial health.
Debt Management: Merck & Co's debt-to-equity ratio is below the industry average. With a ratio of 0.85, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: What Are They?
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
